IBSA Pharma announced the availability of Tirosint-SOL (levothyroxine sodium oral solution) in 3 new dosage strengths: 37.5mcg, 44mcg, and 62.5mcg per mL.
Tirosint-SOL is indicated as a replacement therapy in primary (thyroid), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also approved for use as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
The product is packaged in 1mL unit-dose ampules that contain levothyroxine, glycerol, and water. Each ampule bears a colored label with the dosage strength and the product name. Tirosint-SOL is can be administered in water or directly into the mouth.
In addition to the 3 new dosing options, Tirosint-SOL is available in 12 more strengths: 13mcg/mL, 25mcg/mL, 50mcg/mL, 75mcg/mL, 88mcg/mL, 100mcg/mL, 112mcg/mL, 125mcg/mL, 137mcg/mL, 150mcg/mL, 175mcg/mL, and 200mcg/mL. The new dosage strengths offer health care professionals increased flexibility to meet patient needs.
The Company is also offering the Tirosint-SOL Copay Savings Card to assist eligible patients.
IBSA increases dosage flexibility of liquid hypothyroidism treatment for patients and clinicians; introduces unique new dosing options. News release. IBSA Pharma, Inc. Accessed August 25, 2021. https://www.prnewswire.com/news-releases/ibsa-increases-dosage-flexibility-of-liquid-hypothyroidism-treatment-for-patients-and-clinicians-introduces-unique-new-dosing-options-301362020.html.
This article originally appeared on MPR